GSK2193874

1336960-13-4

C37H38BrF3N4O

DMSO : >= 100 mg/mL (144.59 mM); H2O : < 0.1 mg/mL (insoluble)

Membrane Transporter/Ion Channel; Neuronal Signaling

GSK2193874 is an orally active, potent, and selective TRPV4 antagonist with IC₅₀ of 2 nM and 40 nM for rTRPV4 and hTRPV4. IC50 & Target: IC50: 2 nM (rTRPV4), 40 nM (hTRPV4)^[1] In Vitro: GSK2193874 is profiled against TRP channels and is selective against TRPV1, TRPA1, TRPC3, TRPC6, and TRPM8 (IC₅₀>25 uM)^[1]. GSK2193874 is a selective, orally active TRPV4 blocker that inhibits Ca²⁺ influx through recombinant TRPV4 channels and native endothelial TRPV4 currents. In whole-cell patch-clamp studies, GSK2193874 inhibits activation of recombinant TRPV4 currents when applied to the extracellular solution at 3 nM and above but is ineffective at up to 10 uM when applied to the inside of the cell by inclusion in the intracellular pipette solution^[2]. In Vivo: The pharmacokinetic (PK) properties for GSK2193874 are evaluated in both rat and dog and found to have half-lives and oral exposure suitable for oral dosing in chronic animal models (Rat PK: iv CL=7.3 mL/min/kg, po t_1/2=10 h, %F=31. Dog PK: iv CL=6.9 mL/min/kg, po t_1/2=31 h, %F=53). In addition, GSK2193874 shows no blood pressure or heart rate effect in rats when dose up to 30 mg/kg. GSK2193874 is the first-in-class orally bioavailable TRPV4 inhibitor that demonstrated ability to improve pulmonary functions in a number of heart failure models^[1]. GSK2193874 shows low clearance (7.3 mL/min/kg) and good rat oral bioavailability (31%)^[2].